MY197723A - Vaccine compositions for the prevention of dengue virus infection - Google Patents
Vaccine compositions for the prevention of dengue virus infectionInfo
- Publication number
- MY197723A MY197723A MYPI2018700631A MYPI2018700631A MY197723A MY 197723 A MY197723 A MY 197723A MY PI2018700631 A MYPI2018700631 A MY PI2018700631A MY PI2018700631 A MYPI2018700631 A MY PI2018700631A MY 197723 A MY197723 A MY 197723A
- Authority
- MY
- Malaysia
- Prior art keywords
- prevention
- vaccine compositions
- virus infection
- dengue virus
- vaccine
- Prior art date
Links
- 208000025729 dengue disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010012310 Dengue fever Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305907 | 2012-07-24 | ||
| EP12305912 | 2012-07-25 | ||
| PCT/EP2013/065667 WO2014016360A1 (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY197723A true MY197723A (en) | 2023-07-10 |
Family
ID=48875047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018700631A MY197723A (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for the prevention of dengue virus infection |
| MYPI2014003501A MY168959A (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for the prevention of dengue virus infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014003501A MY168959A (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for the prevention of dengue virus infection |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150196631A1 (https=) |
| EP (2) | EP2877208B1 (https=) |
| JP (2) | JP2015524421A (https=) |
| KR (2) | KR20150036592A (https=) |
| CN (1) | CN104812407B (https=) |
| AU (1) | AU2013295014B2 (https=) |
| MX (2) | MX381497B (https=) |
| MY (2) | MY197723A (https=) |
| PH (1) | PH12014502840B1 (https=) |
| SG (2) | SG10201912291YA (https=) |
| WO (1) | WO2014016360A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013295016A1 (en) * | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| EP2968516B1 (en) | 2013-03-15 | 2022-01-12 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2016130321A1 (en) * | 2015-02-09 | 2016-08-18 | Academia Sinica | An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses |
| EP3316905A1 (en) * | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| EP3147294B1 (en) * | 2015-09-24 | 2020-04-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein |
| KR102373570B1 (ko) * | 2015-11-27 | 2022-03-10 | 케이엠 바이올로직스 가부시키가이샤 | 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신 |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| US11531029B2 (en) | 2017-05-08 | 2022-12-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
| WO2019069130A1 (en) * | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
| US11491217B2 (en) | 2017-12-06 | 2022-11-08 | Emory University | Chimeric viruses encoding mutant zika virus envelope glycoproteins |
| EP3549603A1 (en) | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
| EP3846849A1 (en) | 2018-09-05 | 2021-07-14 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
| CN116334070B (zh) * | 2023-02-15 | 2026-02-06 | 天津大学 | 融合蛋白的应用和细胞融合的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5422A (en) | 1848-02-01 | Spark-arrester | ||
| US109A (en) | 1836-12-15 | Erawijtg | ||
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
| FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| EP0977587B1 (en) | 1997-02-28 | 2005-06-15 | Acambis Inc. | Chimeric flavivirus vaccines |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| WO2000057909A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
| CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| JP2002540169A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱１型ウイルスワクチン |
| ATE526411T1 (de) | 2000-02-16 | 2011-10-15 | Us Gov Health & Human Serv | Avirulente, immunogene flavivirus-chimäre |
| ATE412738T1 (de) | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| CA2966716C (en) | 2001-05-22 | 2019-11-26 | The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| WO2002095007A2 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| CN1551782A (zh) | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
| KR101074175B1 (ko) * | 2002-01-15 | 2011-10-14 | 사노피 파스테르 바이오로직스 씨오 | 플라비바이러스 백신 |
| US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
| CA2611954C (en) | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
| CN101238144B (zh) * | 2005-06-17 | 2012-09-05 | 赛诺菲巴斯德有限公司 | 登革血清型1减毒株 |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| JP5227172B2 (ja) | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
-
2013
- 2013-07-24 SG SG10201912291YA patent/SG10201912291YA/en unknown
- 2013-07-24 KR KR20157003821A patent/KR20150036592A/ko not_active Ceased
- 2013-07-24 MY MYPI2018700631A patent/MY197723A/en unknown
- 2013-07-24 AU AU2013295014A patent/AU2013295014B2/en active Active
- 2013-07-24 MX MX2015000442A patent/MX381497B/es unknown
- 2013-07-24 KR KR1020207016038A patent/KR20200067938A/ko not_active Ceased
- 2013-07-24 CN CN201380049627.XA patent/CN104812407B/zh active Active
- 2013-07-24 MY MYPI2014003501A patent/MY168959A/en unknown
- 2013-07-24 US US14/416,496 patent/US20150196631A1/en not_active Abandoned
- 2013-07-24 SG SG11201500412TA patent/SG11201500412TA/en unknown
- 2013-07-24 EP EP13741748.1A patent/EP2877208B1/en active Active
- 2013-07-24 EP EP21173406.6A patent/EP3932422A1/en active Pending
- 2013-07-24 WO PCT/EP2013/065667 patent/WO2014016360A1/en not_active Ceased
- 2013-07-24 JP JP2015523548A patent/JP2015524421A/ja not_active Ceased
-
2014
- 2014-12-19 PH PH12014502840A patent/PH12014502840B1/en unknown
-
2015
- 2015-01-09 MX MX2021004211A patent/MX2021004211A/es unknown
-
2018
- 2018-09-06 US US16/123,319 patent/US20190201517A1/en not_active Abandoned
-
2019
- 2019-04-03 JP JP2019071529A patent/JP6830118B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200067938A (ko) | 2020-06-12 |
| AU2013295014B2 (en) | 2018-01-18 |
| EP3932422A1 (en) | 2022-01-05 |
| MX381497B (es) | 2025-03-12 |
| MX2015000442A (es) | 2015-03-12 |
| MY168959A (en) | 2019-01-28 |
| PH12014502840A1 (en) | 2015-02-23 |
| US20150196631A1 (en) | 2015-07-16 |
| EP2877208B1 (en) | 2021-05-12 |
| EP2877208A1 (en) | 2015-06-03 |
| PH12014502840B1 (en) | 2015-02-23 |
| SG10201912291YA (en) | 2020-02-27 |
| WO2014016360A1 (en) | 2014-01-30 |
| CA2878682A1 (en) | 2014-01-30 |
| AU2013295014A1 (en) | 2015-01-29 |
| HK1212906A1 (zh) | 2016-06-24 |
| JP6830118B2 (ja) | 2021-02-17 |
| JP2015524421A (ja) | 2015-08-24 |
| CN104812407A (zh) | 2015-07-29 |
| JP2019151636A (ja) | 2019-09-12 |
| SG11201500412TA (en) | 2015-02-27 |
| US20190201517A1 (en) | 2019-07-04 |
| CN104812407B (zh) | 2022-11-22 |
| MX2021004211A (es) | 2021-05-27 |
| KR20150036592A (ko) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY168959A (en) | Vaccine compositions for the prevention of dengue virus infection | |
| PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| PH12018501515B1 (en) | Parenteral novovirus vaccine formulations | |
| PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
| IN2014DN10670A (https=) | ||
| EP2825196A4 (en) | ADJUVANZ AND VACCINE COMPOSITIONS | |
| EP2978449A4 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| EP2931310A4 (en) | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS | |
| SG10201704908SA (en) | Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection | |
| SG11201502221WA (en) | Novel attenuated dengue virus strains for vaccine application | |
| IL236476A0 (en) | Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it | |
| ZA201503844B (en) | Compositions and methods for treating dental caries | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MY171497A (en) | Crystalline forms of dihydropyrimidine derivatives | |
| ZA201307019B (en) | Compositions for preventing and/or treating and infection by an hiv-1 virus | |
| IN2012DE00826A (https=) | ||
| IN2013MU03317A (https=) | ||
| IN2015MN00091A (https=) | ||
| SG11201505170WA (en) | Dengue virus vaccine composition | |
| AU2013369626A1 (en) | Dengue virus vaccine composition | |
| ZA201407866B (en) | Composition for the prevention and treatment of viral infections caused by retroviruses | |
| MX2011007602A (es) | Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus dengue. |